Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

Castle Biosciences Inc (CSTL)

  • Company Report
  • Aug. 08, 2022, 13:07 UTC
  • 31

Castle Biosciences - Second Quarter 2022

Comment Full text

Reata Pharmaceuticals Inc. (RETA)

  • Company Report
  • Aug. 08, 2022, 03:48 UTC
  • 29

Reata Pharmaceuticals Inc. - Second Quarter 2022

Comment Full text

Pacific Biosciences of California Inc (PACB)

  • Company Report
  • Aug. 08, 2022, 03:16 UTC
  • 30

New Form 10-Q for Pacific Biosciences of California Inc

Comment Full text

Incyte Corporation (INCY)

  • Company Report
  • Aug. 05, 2022, 14:41 UTC
  • 30

Weekly Summary Alert for Incyte Corporation

Comment Full text

Codexis Inc. (CDXS)

  • Company Report
  • Aug. 05, 2022, 13:41 UTC
  • 31

New SEC Form for Codexis, Inc.

Comment Full text

BioCryst Pharmaceuticals Inc (BCRX)

  • Company Report
  • Aug. 05, 2022, 13:26 UTC
  • 27

New Form 10-Q for BioCryst Pharmaceutical, Inc.

Comment Full text

Vertex Pharmaceuticals (VRTX)

  • Company Report
  • Aug. 05, 2022, 13:14 UTC
  • 29

New Form 10-Q for Vertex Pharmaceuticals

Comment Full text

Myriad Genetics Inc. (MYGN)

  • Company Report
  • Aug. 05, 2022, 13:11 UTC
  • 29

New Form 10-Q for Myriad Genetics, Inc.

Comment Full text

EyePoint Pharmaceuticals (EYPT)

  • Company Report
  • Aug. 05, 2022, 11:19 UTC
  • 30

New Form 10-Q for EyePoint Pharmaceuticals, Inc.

Comment Full text

Relmada Therapeutics Inc. (RLMD)

  • Company Report
  • Aug. 05, 2022, 07:08 UTC
  • 29

Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

Comment Full text
  • Previous
  • 65
  • 66
  • 67
  • 68
  • 69
  • Next

Search

News categories

  • Technical Exchange News(9358)
  • Event(407)
  • SEC News(152536)
  • FDA Approval(8724)
  • Company Report(721)
  • Business News(104243)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin